Volume 6, Issue 2
Published by AEGIS Communications
Bring Your Patients Back Twice as Fast
It’s the answer you love to give patients: “I have a solution for that.” But until now there has been no solution for patients who complain about lingering numbness, or for those who reluctantly cancel their appointments out of concern that lingering numbness may interfere with their schedule. It’s time to introduce them to OraVerse.
OraVerse (phentolamine mesylate) is the first and only local anesthesia reversal agent that accelerates the return to normal sensation and function following the use of an anesthetic with a vasoconstrictor. OraVerse has been proven effective and safe for adults and children 6 or older and weighing at least 33 lbs. Patients who received OraVerse in clinical trials returned to normal sensation and function approximately twice as fast.
Local anesthetics with vasoconstrictors are used every day in dentistry to help keep patients comfortable during treatment. While pulpal anesthesia usually lasts approximately 45 to 60 minutes, lingering soft tissue anesthesia has an expected duration of 3 to 5 hours, resulting in a prolonged loss of sensation and associated functional deficits. This means patients may have difficulty speaking, smiling, and drinking, or may have a perceived sense of altered appearance. OraVerse provides a solution to address these issues, allowing for a more comfortable dental experience for patients.
A Faster Return to Normal Sensation and Function
OraVerse was studied in three multicenter, double-blinded, randomized, controlled clinical trials involving patients aged 4 through 92. Two adult and adolescent trials were conducted with a total of 484 patients who had restorative or scaling dental procedures and who had received one of four leading anesthetics that contained a vasoconstrictor.1
In mandibular procedures, the median time to recovery of normal lip sensation was 70 minutes for OraVerse patients vs. 155 minutes for the control, or 121% faster. In the maxilla, OraVerse patients recovered lip sensation in a median time of 50 minutes vs. 133 minutes, 166% faster than the control group.
Simple Practice Incorporation
OraVerse is administered in a 1:1 ratio2 to the local anesthetic using the same injection site and an identical technique. It is a vasodilator that has been used in other medical applications since 1952.
OraVerse is recommended specifically for use with patients who have received local anesthetic with a vasoconstrictor and for procedures where post-procedural pain is not anticipated. Some common procedures where OraVerse can be added to the treatment are: cavity and crown preparations, crown placements, inlays, onlays, veneers, and non-surgical periodontal scaling and root planing.
Offering OraVerse presents an opportunity to increase patient satisfaction and differentiate your practice in the market place. Market research shows that the majority of patients feel uncomfortable when they leave the dental office with residual numbness.3 Eighty-seven percent of consumers surveyed expressed interest in receiving OraVerse, even though they knew that it would be a second injection and that there may be an extra charge for the service.
OraVerse can be included as part of the treatment plan, offered as an extra service at an additional fee, or can be incorporated into existing procedural packages and administered as part of the overall treatment. Where patients once may have had to cancel an appointment due to meetings or engagements where functional activity was important, they now can get back to their day and have restored sensation and function when they need it.
Important Safety Information
Following parenteral use of phentolamine at doses between 5 to 15 times higher than the recommended dose of OraVerse (phentolamine mesylate), myocardial infarction, and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia, bradycardia, and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents. See full prescribing information at http://www.novalar.com.
1. Hersh EV, Moore PA, Papas AS, et al. Reversal of soft-tissue local anesthesia with phentolamine mesylate in adolescents and adults. J Am Dent Assoc. 2008;139(80):1080-1093.
2. Data on file. OraVerse was studied in dosages of ½, 1 and 2 cartridges.
3. Data on file. Strategic dental marketing research study of 253 consumers, 2004.
For more information, contact:
Novalar Pharmaceuticals, Inc.
The preceding material was provided by the manufacturer. The statements and opinions contained therein are solely those of the manufacturer and not of the editors, publisher, or the Editorial Board of Inside Dentistry. The preceding is not a warranty, endorsement, or approval for the aforementioned products or services or their effectiveness, quality, or safety on the part of Inside Dentistry or AEGIS Communications. The publisher disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the preceding material.